keyword
MENU ▼
Read by QxMD icon Read
search

Intrathecal therapy

keyword
https://www.readbyqxmd.com/read/29784823/continuous-intrathecal-orexin-delivery-inhibits-cataplexy-in-a-murine-model-of-narcolepsy
#1
Mahesh K Kaushik, Kosuke Aritake, Aya Imanishi, Takashi Kanbayashi, Tadashi Ichikawa, Tetsuo Shimizu, Yoshihiro Urade, Masashi Yanagisawa
Narcolepsy-cataplexy is a chronic neurological disorder caused by loss of orexin (hypocretin)-producing neurons, associated with excessive daytime sleepiness, sleep attacks, cataplexy, sleep paralysis, hypnagogic hallucinations, and fragmentation of nighttime sleep. Currently, human narcolepsy is treated by providing symptomatic therapies, which can be associated with an array of side effects. Although peripherally administered orexin does not efficiently penetrate the blood-brain barrier, centrally delivered orexin can effectively alleviate narcoleptic symptoms in animal models...
May 21, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29776458/hydrocephalus-after-intrathecal-administration-of-dextran-to-rhesus-macaques-macaca-mulatta
#2
Jason P Dufour, Kasi E Russell-Lodrigue, Lara Doyle-Meyers, Kathrine P Falkenstein, Robert V Blair, Elizabeth S Didier, Nadia Slisarenko, Kenneth C Williams, Marcelo J Kuroda
Dextrans have been used extensively as medical therapies and labeling agents in biomedical research to investigate theblood-brain barrier and CSF flow and absorption. Adverse effects from dextrans include anaphylactic reaction and dilation ofthe cerebral ventricles due to administration into the subarachnoid space. This retrospective study describes 51 rhesus macaques(Macaca mulatta) that received dextran intrathecally. The purpose of intrathecal administration was to enable detection oflong-lived, dextran-labeled macrophages and to study monocyte-macrophage turnover in the CNS of SIV- or SHIV- infectedand uninfected animals by using immunofluorescence...
May 18, 2018: Comparative Medicine
https://www.readbyqxmd.com/read/29766026/development-of-intrathecal-aav9-gene-therapy-for-giant-axonal-neuropathy
#3
Rachel M Bailey, Diane Armao, Sahana Nagabhushan Kalburgi, Steven J Gray
An NIH-sponsored phase I clinical trial is underway to test a potential treatment for giant axonal neuropathy (GAN) using viral-mediated GAN gene replacement (https://clinicaltrials.gov/ct2/show/NCT02362438). This trial marks the first instance of intrathecal (IT) adeno-associated viral (AAV) gene transfer in humans. GAN is a rare pediatric neurodegenerative disorder caused by autosomal recessive loss-of-function mutations in the GAN gene, which encodes the gigaxonin protein. Gigaxonin is involved in the regulation, turnover, and degradation of intermediate filaments (IFs)...
June 15, 2018: Molecular Therapy. Methods & Clinical Development
https://www.readbyqxmd.com/read/29753900/dorsal-longitudinal-t-myelotomy-bischof-ii-technique-a-useful-antiquated-procedure-for-treatment-of-intractable-spastic-paraplegia
#4
Bunpot Sitthinamsuwan, Inthira Khampalikit, Luckchai Phonwijit, Akkapong Nitising, Sarun Nunta-Aree, Sirilak Suksompong
OBJECTIVE: Dorsal longitudinal T-myelotomy is a long-established operation to treat severe spastic paraplegia. The present study aimed to report this surgical technique and investigate the efficacy of T-myelotomy for spasticity relief. METHODS: All cases undergoing T-myelotomy for treatment of intractable spastic paraplegia during 2009-2017 were included. The spasticity severity was evaluated using the Modified Ashworth Scale (MAS), Penn Spasm Frequency Scale (PSFS), Adductor Tone Rating Scale (ATRS), degree of passive range of motion (PROM), and occurrence of abdominal muscle spasms...
May 10, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29742888/atypical-teratoid-rhabdoid-tumour-from-tumours-to-therapies
#5
REVIEW
Elizabeth Anne Richardson, Ben Ho, Annie Huang
Atypical teratoid rhabdoid tumours (ATRTs) are the most common malignant central nervous system tumours in children ≤1 year of age and represent approximately 1-2% of all pediatric brain tumours. ATRT is a primarily monogenic disease characterized by the bi-allelic loss of the SMARCB1 gene, which encodes the hSNF5 subunit of the SWI/SNF chromatin remodeling complex. Though conventional dose chemotherapy is not effective in most ATRT patients, high dose chemotherapy with autologous stem cell transplant, radiotherapy and/or intrathecal chemotherapy all show significant potential to improve patient survival...
May 2018: Journal of Korean Neurosurgical Society
https://www.readbyqxmd.com/read/29742241/therapeutic-advances-in-5q-linked-spinal-muscular-atrophy
#6
Umbertina Conti Reed, Edmar Zanoteli
Spinal muscular atrophy (SMA) is a severe and clinically-heterogeneous motor neuron disease caused, in most cases, by a homozygous mutation in the SMN1 gene. Regarding the age of onset and motor involvement, at least four distinct clinical phenotypes have been recognized. This clinical variability is, in part, related to the SMN2 copy number. By now, only supportive therapies have been available. However, promising specific therapies are currently being developed based on different mechanisms to increase the level of SMN protein; in particular, intrathecal antisense oligonucleotides that prevent the skipping of exon 7 during SMN2 transcription, and intravenous SMN1 insertion using viral vector...
April 2018: Arquivos de Neuro-psiquiatria
https://www.readbyqxmd.com/read/29741758/excellent-real-world-outcomes-of-adults-with-burkitt-lymphoma-treated-with-codox-m-ivac-plus-or-minus-rituximab
#7
Katie Y Zhu, Kevin W Song, Joseph M Connors, Heather Leitch, Michael J Barnett, Khaled Ramadan, Graham W Slack, Yasser Abou Mourad, Donna L Forrest, Donna E Hogge, Stephen H Nantel, Sujaatha Narayanan, Thomas J Nevill, Maryse M Power, David S Sanford, Heather J Sutherland, Tracy Tucker, Cynthia L Toze, Laurie H Sehn, Raewyn Broady, Alina S Gerrie
Treatment of Burkitt lymphoma (BL) with intensive, multi-agent chemotherapy with aggressive central nervous system (CNS) prophylaxis results in high cure rates, although no regimen is standard of care. We examined population-based survival outcomes of adults with BL treated with a modified combination of cyclophosphamide, vincristine, doxorubicin, prednisone and systemic high-dose methotrexate (MTX) (CODOX-M) with IVAC (ifosfamide, mesna, etoposide, cytarabine and intrathecal MTX) (CODOX-M/IVAC) ± rituximab over a 15-year period in British Columbia...
May 9, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29729779/interventional-anesthetic-methods-for-pain-in-hematology-oncology-patients
#8
REVIEW
Holly Careskey, Sanjeet Narang
This article reviews anesthetic interventional approaches to the management of pain in hematology and oncology patients. It includes a discussion of single interventions including peripheral nerve blocks, plexus injections, and sympathetic nerve neurolysis, and continuous infusion therapy through implantable devices, such as intrathecal pumps, epidural port-a-caths, and tunneled catheters. The primary objective is to inform members of hematology and oncology care teams regarding the variety of interventional options for patients with cancer-related pain for whom medical pain management methods have not been effective...
June 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29719742/toxic-myelitis-and-arachnoiditis-after-intrathecal-delivery-of-bupivacaine-via-an-implanted-drug-delivery-system-case-report-and-review-of-the-literature
#9
Meng Huang, Brian Dalm, Richard K Simpson
The off-label usage of amino-amide anesthetics in intrathecal drug delivery systems (IDDS) for the treatment of chronic non-malignant and malignant pain is supported in the polyanalgesic consensus guidelines as a second-line adjunctive therapy. Although strong evidence for its clinical efficacy is lacking, its clinical safety profile has been well established within established dosing parameters. Despite the rarity of neurological adverse reactions to intrathecal bupivacaine, whether given as regional anesthesia or intrathecal therapy, neurologic morbidity associated with its administration is well documented...
February 27, 2018: Curēus
https://www.readbyqxmd.com/read/29666729/posttransplant-lymphoproliferative-disorder-presenting-as-testicular-lymphoma-in-a-kidney-transplant-recipient-a-case-report-and-review-of-the-literature
#10
Steve Omoruyi Obanor, Michelle Gruttadauria, Kayla Applebaum, Mohammad Eskandari, Michelle Lieberman Lubetzky, Stuart Greenstein
Posttransplant lymphoproliferative disorder (PTLD) is a malignancy caused by the immunosuppression that occurs after transplantation. It is primarily a nodal lesion but frequently it involves extranodal masses. Treatment is usually by reducing immunosuppressive therapy. Testicular lymphoma as PTLD is notably rare in documented literature and there is limited evidence of definitive treatment guidelines. This manuscript describes a patient who developed diffuse large B-cell lymphoma of his right testis one year following kidney transplantation...
2018: Case Reports in Nephrology
https://www.readbyqxmd.com/read/29661806/daclizumab-therapy-for-multiple-sclerosis
#11
Bibiana Bielekova
Daclizumab is a humanized monoclonal antibody that prevents formation of high-affinity interleukin (IL)-2 receptor (IL-2R). Because activated T cells up-regulate high-affinity IL-2R and IL-2 is used to grow activated T cells in vitro, daclizumab was envisioned to selectively inhibit activated T cells. However, the mechanism of action (MOA) of daclizumab is surprisingly broad and it includes many unanticipated effects on innate immunity. Specifically, daclizumab modulates the development of innate lymphoid cells, leading to expansion of immunoregulatory CD56bright natural killer (NK) cells...
April 16, 2018: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/29660974/in-vivo-spinal-distribution-of-cy5-5-fluorescent-dye-after-injection-via-the-lateral-ventricle-and-cisterna-magna-in-rat-model
#12
Kee-Hang Lee, Hyun Nam, Jeong-Seob Won, Ji-Yoon Hwang, Hye Won Jang, Sun-Ho Lee, Kyeung Min Joo
Objective: The purpose of this study was to find an optimal delivery route for clinical trials of intrathecal cell therapy for spinal cord injury in preclinical stage. Methods: We compared in vivo distribution of Cy5.5 fluorescent dye in the spinal cord region at various time points utilizing in vivo optical imaging techniques, which was injected into the lateral ventricle (LV) or cisterna magna (CM) of rats. Results: Although CM locates nearer to the spinal cord than the LV, significantly higher signal of Cy5...
April 18, 2018: Journal of Korean Neurosurgical Society
https://www.readbyqxmd.com/read/29657936/cellular-therapy-for-chronic-traumatic-brachial-plexus-injury
#13
Alok Sharma, Hemangi Sane, Nandini Gokulchandran, Prerna Badhe, Suhasini Pai, Pooja Kulkarni, Jayanti Yadav, Sanket Inamdar
Cellular therapy is being actively pursued as a therapeutic modality in many of the neurological diseases. A variety of stem cells from diverse sources have been studied in detail and have been shown to exhibit angiogenetic and immunomodulatory properties in addition to other neuroprotective effects. Published clinical data have shown bone marrow mononuclear cell (BMMNC) injection in neurological disorders is safe and possesses regenerative potential. We illustrate a case of 27-year-old male with traumatic brachial plexus injury, administered with autologous BMMNCs intrathecally and intramuscularly, followed by multidisciplinary rehabilitation...
2018: Advanced Biomedical Research
https://www.readbyqxmd.com/read/29651352/prolonged-survival-of-acute-lymphoblastic-leukemia-with-intrathecal-treatments-for-isolated-central-nervous-system-relapse
#14
Elan Gorshein, Sheila Kalathil, Mecide Gharibo
Acute lymphoblastic leukemia is commonly cured when diagnosed in the pediatric population. It portends a poorer prognosis if present in adult patients. Although adults frequently achieve complete remission, relapse rates are substantial, particularly among the elderly and high-risk populations. In the absence of prophylactic intrathecal chemotherapy, more than half of patients may develop CNS involvement or relapse, which is associated with significant risk for systemic illness. This report describes a patient with acute lymphoblastic leukemia with repeated isolated CNS relapses...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/29626288/evidence-for-intrathecal-sodium-butyrate-as-a-novel-option-for-leptomeningeal-metastasis
#15
Hidemitsu Nakagawa, Yoshihiro Yui, Satoru Sasagawa, Kazuyuki Itoh
INTRODUCTION: The prognosis for leptomeningeal metastasis (LM) remains extremely poor regardless of intrathecal chemotherapy with various drugs, and thus, new treatments are necessary. Butyrate is an endogenous 4-carbon saturated fatty acid, has been investigated as an anti-tumor agent because of its multiple suppressive effects on several tumors. In this study, we investigated the cellular basis of sodium butyrate (SB), a sodium salt compound of butyrate, in vitro and evaluated the clinical potential of intrathecal SB administration for LM in vivo...
April 6, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29620662/good-outcomes-after-the-delayed-removal-of-an-epidural-hematoma-a-case-report
#16
Yong-Xing Yao, Ming-Xia Li, Lian-Juan Sun
RATIONALE: Epidural hematomas can develop following intrathecal puncture, spinal vascular malformation, or spontaneous hemorrhage. Prompt recognition of symptoms and referral to neurosurgical services are crucial for recovery. We report a rare case of delayed removal of an epidural hematoma that resulted in good patient outcomes. PATIENT CONCERNS: A 69-year-old woman weighing 58 kg presented with back pain that had persisted for 12 years. Her medical history was notable for hypertension...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29617640/rna-targeted-therapeutics
#17
REVIEW
Stanley T Crooke, Joseph L Witztum, C Frank Bennett, Brenda F Baker
RNA-targeted therapies represent a platform for drug discovery involving chemically modified oligonucleotides, a wide range of cellular RNAs, and a novel target-binding motif, Watson-Crick base pairing. Numerous hurdles considered by many to be impassable have been overcome. Today, four RNA-targeted therapies are approved for commercial use for indications as diverse as Spinal Muscular Atrophy (SMA) and reduction of low-density lipoprotein cholesterol (LDL-C) and by routes of administration including subcutaneous, intravitreal, and intrathecal delivery...
April 3, 2018: Cell Metabolism
https://www.readbyqxmd.com/read/29614489/hyperbaric-oxygen-therapy-as-adjuvant-treatment-for-hardware-related-infections-in-neuromodulation
#18
Jiri Bartek, Simon Skyrman, Michael Nekludov, Tiit Mathiesen, Folke Lind, Gaston Schechtmann
BACKGROUND: In neuromodulation therapies, hardware-related infections are a major challenge often leading to hardware removal. OBJECTIVE: To investigate the role of adjuvant hyperbaric oxygen therapy (HBOT) in hardware-related infections. METHODS: Fourteen hardware-related infection events in 12 consecutive patients between 2002 and 2015 were treated with antibiotics and adjuvant HBOT at the Karolinska University Hospital (Stockholm, Sweden)...
April 3, 2018: Stereotactic and Functional Neurosurgery
https://www.readbyqxmd.com/read/29607891/effects-of-leucovorin-folinic-acid-in-the-methotrexate-treated-rat-brain
#19
Naofumi Ogushi, Kazuaki Sasaki, Minoru Shimoda
Folinic acid (FA) is generally administered to patients with CNS tumors in order to treat severe neurological disorders caused by methotrexate (MTX); therefore, we herein examined the effects of the co-administration of FA on MTX concentrations in the rat brain and cerebrospinal fluid (CSF) as well as the pharmacokinetics of MTX. MTX was intravenously or intrathecally administered to rats with or without FA. MTX concentrations were assessed by HPLC. No significant differences were observed in pharmacokinetic parameters, including kel , Vd , AUC, Cltot , and t1/2 , between the FA-treated and non-treated groups...
March 30, 2018: Journal of Veterinary Medical Science
https://www.readbyqxmd.com/read/29596541/association-of-cerebrospinal-fluid-biomarkers-of-central-nervous-system-injury-with-neurocognitive-and-brain-imaging-outcomes-in-children-receiving-chemotherapy-for-acute-lymphoblastic-leukemia
#20
Yin Ting Cheung, Raja B Khan, Wei Liu, Tara M Brinkman, Michelle N Edelmann, Wilburn E Reddick, Deqing Pei, Angela Panoskaltsis-Mortari, Deokumar Srivastava, Cheng Cheng, Leslie L Robison, Melissa M Hudson, Ching-Hon Pui, Kevin R Krull
Importance: Little is known about treatment-related neurotoxic mechanisms in children with acute lymphoblastic leukemia (ALL) treated with chemotherapy only. Objective: To examine concentration of cerebrospinal fluid (CSF) biomarkers of brain injury at ALL diagnosis and during cancer therapy and to evaluate associations with long-term neurocognitive and neuroimaging outcomes and relevant genetic polymorphisms. Design, Setting, and Participants: This prospective cohort study included 235 patients with ALL who received a chemotherapy-only protocol...
March 29, 2018: JAMA Oncology
keyword
keyword
22826
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"